Obermatt
See Similar Stocks →

Relay Therapeutics

NMQ:RLAY · US75943R1023
BiotechnologySmall

360

23
Profit price58
Cash yield1
Price/Sales14
Price/Book24
Return on Capital31
Cash Return on Capital32
Return on Equity34
Profit margins9
Accruals88
Owner Earnings Margin13
Sales growth33
Profit growth23
Reinvestment97
Price momentum90
Debt load46
Refinancing77
Debt Payback1
Liquidity52
Analyst ratings79
Opinion Changes68
Price Target Upside57
Market mood49
Value Creation6/20not creating value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Relay Therapeutics doesn't consistently earn more than its cost of capital, so it isn't yet creating shareholder value.

Profile

CountryUSA
IndustryBiotechnology
SizeSmall
TypePublic Company
ExchangeNASDAQGM
Founded2015
Employees199
Websiterelaytx.com
ISINUS75943R1023
Last UpdateApr 2, 2026
Indices
NASDAQ (USA)
Themes
Machine LearningArtificial IntelligenceGeneticsOncologyGenetic DisorderBiotechnologyHealth CareTherapeutics

Description

Relay Therapeutics, Inc. (Relay Therapeutics) is a clinical-stage precision medicine company. The company develops therapies for patients living with cancer and genetic disease. The company’s Dynamo platform integrates an array of computational and…

Analysis

Middle-of-the-road

Relay Therapeutics, Inc. sits in the middle of our grid: average quality, average price, no obvious signal in either direction.

Valuation data is not available for this company.

Growth is moderate; the safety picture is adequate. The company scores 6/20 on our value-creation score: not creating value.

No flags apply to this company at this time: accounts, balance sheet, and cash quality all pass. A clean bill of health is meaningful, not just the absence of a warning. This analysis describes numbers; it is not investment advice.

360° rank · history

1007550250
74
2026

All-time high

74

Jun 2026

All-time low

64

Mar 2026

Average rank

69

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
14
—
—
—
Price/Earnings
71
—
—
—
Price/Book
24
—
—
—
Dividend Yield
—
—
—
—
Value (overall)
24
—
—
—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Relay Therapeutics with its peers
Revolution Medicines
NSQ:RVMD
32
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
IDEAYA Biosciences
NSQ:IDYA
18
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Kymera Therapeutics
NMQ:KYMR
30
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Charles River Laboratories
NYQ:CRL
17
CountryUSA
IndustryLife Sciences Tools & Services
SizeX-Large
Full Stock Analysis →
Sangamo Therapeutics
NAQ:SGMO
34
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
BridgeBio Oncology Therapeutics
NMQ:BBOT
—
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →